Scott W Hiebert

List of Publications by Year
in descending order

87	6,168	71061 41	71651 76
papers	citations	h-index	g-index

93	93	93	8123
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ETO, a Target of t(8;21) in Acute Leukemia, Interacts with the N-CoR and mSin3 Corepressors. Molecular and Cellular Biology, 1998, 18, 7176-7184.	1.1	417
2	Analysis of protein dynamics at active, stalled, and collapsed replication forks. Genes and Development, 2011, 25, 1320-1327.	2.7	368
3	ETO, a Target of t(8;21) in Acute Leukemia, Makes Distinct Contacts with Multiple Histone Deacetylases and Binds mSin3A through Its Oligomerization Domain. Molecular and Cellular Biology, 2001, 21, 6470-6483.	1.1	316
4	Deletion of Histone Deacetylase 3 Reveals Critical Roles in S Phase Progression and DNA Damage Control. Molecular Cell, 2008, 30, 61-72.	4.5	314
5	Hdac3 Is Essential for the Maintenance of Chromatin Structure and Genome Stability. Cancer Cell, 2010, 18, 436-447.	7.7	305
6	The t(8;21) fusion protein, AML1â€“ETO, specifically represses the transcription of the p14ARF tumor suppressor in acute myeloid leukemia. Nature Medicine, 2002, 8, 743-750.	15.2	258
7	Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO Journal, 2008, 27, 1017-1028.	3.5	238
8	The coactivator role of histone deacetylase 3 in IL-1-signaling involves deacetylation of p65 NF-Î¹B. Nucleic Acids Research, 2013, 41, 90-109.	6.5	218
9	CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discovery, 2017, 7, 38-53.	7.7	218
10	Germinal centre hypoxia and regulation of antibody qualities by a hypoxia response system. Nature, 2016, 537, 234-238.	13.7	215
11	The MYND Motif Is Required for Repression of Basal Transcription from the Multidrug Resistance 1 Promoter by the t(8;21) Fusion Protein. Molecular and Cellular Biology, 1998, 18, 3604-3611.	1.1	176
12	Role of RUNX family members in transcriptional repression and gene silencing. Oncogene, 2004, 23, 4220-4224.	2.6	160
13	Both TEL and AML-1 Contribute Repression Domains to the t(12;21) Fusion Protein. Molecular and Cellular Biology, 1999, 19, 6566-6574.	1.1	149
14	The inv(16) Fusion Protein Associates with Corepressors via a Smooth Muscle Myosin Heavy-Chain Domain. Molecular and Cellular Biology, 2003, 23, 607-619.	1.1	148
15	Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene, 2001, 20, 6983-6993.	2.6	138
16	The ETO Protein Disrupted in t(8;21)-Associated Acute Myeloid Leukemia Is a Corepressor for the Promyelocytic Leukemia Zinc Finger Protein. Molecular and Cellular Biology, 2000, 20, 2075-2086.	1.1	134
17	Small ubiquitin-like modifier conjugation regulates nuclear export of TEL, a putative tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3257-3262.	3.3	107
18	Mammalian runt-domain proteins and their roles in hematopoiesis, osteogenesis, and leukemia. Journal of Cellular Biochemistry, 1999, 75, 51-58.	1.2	100

#	Article	IF	Citations
19	TEL, a Putative Tumor Suppressor, Modulates Cell Growth and Cell Morphology of Ras-Transformed Cells While Repressing the Transcription of stromelysin-1. Molecular and Cellular Biology, 2000, 20, 5828-5839.	1.1	96
20	TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3. Oncogene, 2001, 20, 3716-3725.	2.6	87
21	Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma. PLoS ONE, 2013, 8, e68915.	1.1	87
22	CBFa(AML/PEBP2)-related elements in the TGF-Î² type I receptor promoter and expression with osteoblast differentiation. Journal of Cellular Biochemistry, 1998, 69, 353-363.	1.2	83
23	Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity. Cell Reports, 2019, 26, 2916-2928.e13.	2.9	70
24	HDAC3 is essential for DNA replication in hematopoietic progenitor cells. Journal of Clinical Investigation, 2013, 123, 3112-3123.	3.9	70
25	Deletion of Mtg16, a Target of t(16;21), Alters Hematopoietic Progenitor Cell Proliferation and Lineage Allocation. Molecular and Cellular Biology, 2008, 28, 6234-6247.	1.1	69
26	High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. Cell Reports, 2016, 16, 2003-2016.	2.9	69
27	HDAC3 is a molecular brake of the metabolic switch supporting white adipose tissue browning. Nature Communications, 2017, 8, 93.	5.8	68
28	Nascent RNA sequencing analysis provides insights into enhancer-mediated gene regulation. BMC Genomics, 2018, 19, 633.	1.2	60
29	AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood, 2000, 96, 3939-3947.	0.6	59
30	Translating the histone code into leukemia. Journal of Cellular Biochemistry, 2005, 96, 938-950.	1.2	57
31	Mtgr1 Is a Transcriptional Corepressor That Is Required for Maintenance of the Secretory Cell Lineage in the Small Intestine. Molecular and Cellular Biology, 2005, 25, 9576-9585.	1.1	56
32	Role of histone deacetylases in acute leukemia. , 1998, 72, 194-202.		54
33	Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiotherapy and Oncology, 2016, 119, 312-318.	0.3	51
34	ETO family protein Mtg16 regulates the balance of dendritic cell subsets by repressing Id2. Journal of Experimental Medicine, 2014, 211, 1623-1635.	4.2	49
35	Mammalian runtâ€domain proteins and their roles in hematopoiesis, osteogenesis, and leukemia. Journal of Cellular Biochemistry, 1999, 75, 51-58.	1.2	49
36	Histone Deacetylase 3 Is Required for T Cell Maturation. Journal of Immunology, 2015, 195, 1578-1590.	0.4	47

#	Article	IF	Citations
37	Human sterol 14Î±-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design. Journal of Lipid Research, 2016, 57, 1552-1563.	2.0	47
38	Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies. Cancer Research, 2016, 76, 736-748.	0.4	46
39	Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Science Translational Medicine, 2020, 12, .	5.8	46
40	The transcriptional repressor NKAP is required for the development of iNKT cells. Nature Communications, 2013, 4, 1582.	5.8	45
41	Definition of a small core transcriptional circuit regulated by AML1-ETO. Molecular Cell, 2021, 81, 530-545.e5.	4.5	45
42	Histone Deacetylase 3 Is Required for Efficient T Cell Development. Molecular and Cellular Biology, 2015, 35, 3854-3865.	1.1	44
43	Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy. Antioxidants and Redox Signaling, 2015, 23, 51-65.	2.5	44
44	Myeloid Translocation Gene Family Members Associate with T-Cell Factors (TCFs) and Influence TCF-Dependent Transcription. Molecular and Cellular Biology, 2008, 28, 977-987.	1.1	43
45	Transcriptional Repression of the Neurofibromatosis-1 Tumor Suppressor by the t(8;21) Fusion Protein. Molecular and Cellular Biology, 2005, 25, 5869-5879.	1.1	42
46	E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation. Oncogene, 2001, 20, 910-920.	2.6	38
47	Autofluorescence imaging identifies tumor cellâ€cycle status on a singleâ€cell level. Journal of Biophotonics, 2018, 11, e201600276.	1.1	35
48	Subcellular partitioning of transcription factors during osteoblast differentiation: Developmental association of the AML/CBFÎ±/PEBP2Î±-related transcription factor-NMP-2 with the nuclear matrix. Journal of Cellular Biochemistry, 1997, 66, 123-132.	1.2	33
49	Identification of active miRNA promoters from nuclear run-on RNA sequencing. Nucleic Acids Research, 2017, 45, e121-e121.	6.5	32
50	The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5â€² and 3â€² ends of genes. Nucleic Acids Research, 2019, 47, 3921-3936.	6.5	30
51	Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins. Cancer Chemotherapy and Pharmacology, 2001, 48, S31-S34.	1.1	27
52	Deletion of Mtgr1 Sensitizes the Colonic Epithelium to Dextran Sodium Sulfateâ€“Induced Colitis. Gastroenterology, 2006, 131, 579-588.	0.6	27
53	Myeloid Translocation Gene 16 (MTG16) Interacts with Notch Transcription Complex Components To Integrate Notch Signaling in Hematopoietic Cell Fate Specification. Molecular and Cellular Biology, 2010, 30, 1852-1863.	1.1	27
54	Mtg16/Eto2 Contributes to Murine T-Cell Development. Molecular and Cellular Biology, 2011, 31, 2544-2551.	1.1	27

#	Article	IF	Citations
55	TEL, a Putative Tumor Suppressor, Induces Apoptosis and Represses Transcription of Bcl-XL. Journal of Biological Chemistry, 2003, 278, 46378-46386.	1.6	26
56	Eto2/MTG16 and MTGR1 are heteromeric corepressors of the TAL1/SCL transcription factor in murine erythroid progenitors. Biochemical and Biophysical Research Communications, 2009, 390, 295-301.	1.0	25
57	MTG16 contributes to colonic epithelial integrity in experimental colitis. Gut, 2013, 62, 1446-1455.	6.1	22
58	Deacetylase activity of histone deacetylase 3 is required for productive VDJ recombination and B-cell development. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8608-8613.	3.3	22
59	The t(8;21) fusion protein contacts co-repressors and histone deacetylases to repress the transcription of the p14ARF tumor suppressor. Blood Cells, Molecules, and Diseases, 2003, 30, 177-183.	0.6	20
60	Transcriptional corepressor MTG16 regulates small intestinal crypt proliferation and crypt regeneration after radiation-induced injury. American Journal of Physiology - Renal Physiology, 2015, 308, G562-G571.	1.6	20
61	Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia. Gene, 2020, 752, 144758.	1.0	17
62	BET inhibitors reduce cell size and induce reversible cell cycle arrest in AML. Journal of Cellular Biochemistry, 2019, 120, 7309-7322.	1.2	16
63	BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia. Clinical Cancer Research, 2021, 27, 598-607.	3.2	16
64	Role for histone deacetylase 3 in maintenance of genome stability. Cell Cycle, 2011, 10, 727-728.	1.3	15
65	Alterations in subnuclear trafficking of nuclear regulatory factors in acute leukemia. Journal of Cellular Biochemistry, 2000, 79, 93-98.	1.2	14
66	Cellular stress triggers TEL nuclear export via two genetically separable pathways. Journal of Cellular Biochemistry, 2008, 104, 488-498.	1.2	14
67	Histone deacetylase 3 controls a transcriptional network required for B cell maturation. Nucleic Acids Research, 2019, 47, 10612-10627.	6.5	14
68	The transcriptional corepressor MTGR1 regulates intestinal secretory lineage allocation. FASEB Journal, 2015, 29, 786-795.	0.2	13
69	Kaiso is required for MTG16-dependent effects on colitis-associated carcinoma. Oncogene, 2019, 38, 5091-5106.	2.6	10
70	MTG16 regulates colonic epithelial differentiation, colitis, and tumorigenesis by repressing E protein transcription factors. JCI Insight, 2022, 7, .	2.3	9
71	Over-Generalizing About GC (Hypoxia): Pitfalls of Limiting Breadth of Experimental Systems and Analyses in Framing Informatics Conclusions. Frontiers in Immunology, 2021, 12, 664249.	2.2	8
72	A protocol for rapid degradation of endogenous transcription factors in mammalian cells and identification of direct regulatory targets. STAR Protocols, 2021, 2, 100530.	0.5	8

#	Article	IF	Citations
73	Epigenetic regulation of tumor suppressors in t(8:21)-containing AML. Annals of Hematology, 2004, 83, 329-330.	0.8	6
74	MTG16 is a tumor suppressor in colitis-associated carcinoma. JCI Insight, 2017, 2, .	2.3	6
75	Topoisomerase IIÎ± Mediates E2F-1-Induced Chemosensitivity and Is a Target for p53-Mediated Transcriptional Repression. Cell Biochemistry and Biophysics, 2000, 33, 199-207.	0.9	5
76	Inactivation of the p19^{ARF} tumor suppressor affects intestinal epithelial cell proliferation and integrity. Journal of Cellular Biochemistry, 2008, 104, 2228-2240.	1.2	4
77	Phase I trial of chemoradiation with capecitabine and vorinostat in pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, 225-225.	0.8	3
78	Eto2/MTG16 Regulates E-Protein Activity and Subset Specification in Dendritic Cell Development. Blood, 2012, 120, 1229-1229.	0.6	3
79	Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation. Targeted Oncology, 2021, 16, 663-674.	1.7	2
80	RUNX1/AML1 DNA Binding Domain and ETO/MTG8 NHR2 Dimerization Domain Are Critical to AML1â"ETO9a Leukemogenesis.. Blood, 2006, 108, 772-772.	0.6	1
81	Proteomic Identification of TAL1/SCL-Interacting Proteins: ETO-2 and MTGR1 Interact with TAL1 in Erythroid Progenitors.. Blood, 2004, 104, 357-357.	0.6	0
82	Establishment of a Retroviral Mouse Model for inv(16)-Mediated Acute Myeloid Leukemia Suggests That the p14ARF Tumor Suppressor Is a Transcriptional Target for Repression by the inv(16) Fusion Protein.. Blood, 2004, 104, 547-547.	0.6	0
83	Multimerization and Corepression Mediated by the CBFÎ²-SMMHC Assembly Competence Domain Are Partially Separable and Corepression Is Required to Inhibit Core Binding Factor Activities.. Blood, 2004, 104, 1972-1972.	0.6	0
84	RUNX1 Directly Regulates Band 3 Transcription.. Blood, 2005, 106, 1735-1735.	0.6	0
85	Mutational Analysis of the CBFÎ²-SMMHC Assembly Competence Domain Identifies a Surface Critical for Multimerization and Inhibition of RUNX1/AML1.. Blood, 2005, 106, 2853-2853.	0.6	0
86	High Resolution Mapping of Active RNA Polymerases Identifies KIT As a Target of BET Inhibitors in t(8;21) AML. Blood, 2015, 126, 1225-1225.	0.6	0
87	The BET Inhibitor INCB054329 Primes AML Cells for Venetoclax-Induced Apoptosis. Blood, 2018, 132, 4074-4074.	0.6	0